Protocol Ledger

Academic / Cooperative Group · Consolidated Sponsor Hub

Washington University School of Medicine: Clinical Trials & FDA Approval Profile

Washington University School of Medicine (Saint Louis, MO) sponsors 192 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 87 active protocols (48 recruiting now), 52 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)26.6%
Median Closed Enrollment vs National (145 pts)34 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Washington University School of Medicine
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)192
Active Pipeline (Recruiting Now)87 (48)
Completed vs Stopped Early52 / 51 (26.6%)
Median Closed Actual Enrollment34 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Washington University School of Medicine
Hospital Research SiteLocationShared Protocols
Washington University and Siteman Cancer CenterSaint Louis, MO158
University of WashingtonSeattle, WA5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Washington University School of Medicine
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06647498A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPhase II/IIIRECRUITING
NCT05552157A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPhase II/IIIRECRUITING
NCT05269394Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in IndivPhase II/IIIACTIVE NOT RECRUITING
NCT03735979Multi-arm Optimization of Stroke ThrombolysisPhase IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Washington University School of Medicine Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI